CSI Market
Sign In | Register

Rafael Holdings Inc (RFL) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RFL Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Rafael Holdings Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Apr 30 2026)
9 Months 		(Oct 31 2025) (Jul 31 2025) (Apr 30 2025) (Jan 31 2025)
Operating Activities
Income-19.02
Depreciation & amortization0.15
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.01
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.05
Share-based Compensation1.16
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Interestincome On Series Convertible Notes-
Marketable Securities Gain Loss-
Realized Gain On Disposal Of Bonus Shares-
Interest Expense Related Party-
Gain Loss On Investments Hedge Fund-
Impairment Of Investments-
Increase Decrease In Due From Related Parties Current One-
Increase Decrease In Due From Rafael Pharmaceuticals-
Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest-
Impairment Of Cost Method Investment Rafael Pharmaceuticals-
Realized Gain In Equity Investments Cyclo Therapeutics Inc-
Unrealized Loss In Equity Investments Cyclo Therapeutics Inc-
Unrealized Gain On Investment Hedge Funds-
Impairment Of Cost Method Investment-
Loss On Initial Investment In Day Three Upon Acquisition-
Recovery Of Receivables-
Inprocess Research And Development Expense-
Debt Securities Realized Gain Loss-
Unrealized Gain On Convertible Notes Receivable Due From Cyclo-
Increase Decrease In Convertible Notes Payable0.01
Gain Loss On Sale Of Interest In Projects-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable1.36
Increase (Decrease) in Due to Related Parties, Current-0.01
Increase (Decrease) in Accrued Liabilities-0.41
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-0.81
Other Working Capital-0.04
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.96
Discontinued operations0.00
Net Cash flow from Operating Activities-21.61
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.08
Proceeds from Sale of Held-to-maturity Securities0.00
Payments to Acquire Held-to-maturity Securities0.00
Real Estate Investments0.00
Investment In Altira-
Payment To Fund R P Finance Line Of Credit-
Payment To Rafael Pharmaceuticals Pursuant To Line Of Credit-
Payment Of Transaction Costs For Sale-
Proceeds From Investments Other Pharmaceuticals-
Payments To Acquire Equity Securities Fv Ni-
Proceeds From Sale Of Equity Securities Fv Ni-
Proceeds From Day Three Patent Sale-
Purchase Of Preferred Shares And Warrants From Nina Medical-0.75
Proceeds From The Sale And Maturities Of Availableforsale Securities-
Issuance Of Convertible Notes Due From Cyclo-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale and Maturity of Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses and Interests in Affiliates0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Proceeds from Decommissioning Trust Fund Assets0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.68
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-52.86
Payments For Taxes Related To Shares Withheld For Employee Taxes-
Amount Due For Purchase Of Membership Interest-
Transfer Of Asset Held For Sale-
Conversion Of Lipomedix Bridge Note-
Conversion Of Related Party Convertible Notes Payable And Accrued Interest-
Contribution From Noncontrolling Interest Of Consolidated Entity-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents52.77
Acquisition Of Additional Ownership Interest In Lipo Medix-
Proceeds From Issuance Of Common Stock From Related Party-
Payment of Note Payableinconnectionwithsale-
Proceeds From Sale Of R M D Membership Units-
Payment Of Note Payable In Connection With Sale Of520 Property Discontinued Operations-
Payment Of Note Payable In Connection With Sale Of Property Discontinued Operations-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.09
Effect of exchange rate on cash flow0.11
Discontinued operations0.00
Free Cash Flow-21.54
Total Cash Flow-22.27
4 historic quarters locked

Sign in to unlock the full Rafael Holdings Inc cash flow history.

Sign In Create Free Account

About Rafael Holdings Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-067560

Figures are derived from filed reports and may be restated. Historical data is subject to revision.